Sorafenib inhibits p38α activity in colorectal cancer cells and synergizes with the DFG-in inhibitor SB202190 to increase apoptotic response

Cancer Biology and Therapy

Volumn 13, Issue 14, 2012, Pages 1471-1481

  Grossi, Valentina ^a   Liuzzi, Micaela ^b   Murzilli, Stefania ^c,d   Martelli, Nicola ^c,d   Napoli, Anna ^b   Ingravallo, Giuseppe ^b   Del Rio, Alberto ^e   Simone, Cristiano ^b,f  

^a NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c Laboratory of Lipid Metabolism and Cancer   (Italy)

^d Alma Mater Studiorum University of Bologna ^*  (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f Laboratory of Signal dependent Transcription   (Italy)

Author keywords

Apoptosis; BRAF; Colorectal cancer; Conformations; DFG in and DFG out; MEK ERK; P38 ; Protein kinase; Sorafenib; Type I and type II inhibitors

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ASPARAGINE; GLYCINE; MITOGEN ACTIVATED PROTEIN KINASE 14; PHENYLALANINE; SORAFENIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME INHIBITION; FEMALE; MOUSE; NONHUMAN;

ANIMALS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG SYNERGISM; FEMALE; HUMANS; IMIDAZOLES; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 14; NEOPLASM TRANSPLANTATION; NIACINAMIDE; PHENYLUREA COMPOUNDS; PYRIDINES; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84870658890     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.22254     Document Type: Article

References (28)

1. Chiacchiera F, Simone C. Signal-dependent regulation of gene expression as a target for cancer treatment: inhibiting p38alpha in colorectal tumors. Cancer Lett 2008; 265:16-26; PMID:18395970; http://dx.doi.org/10.1016/j.canlet. 2008.02.061.
2. Segal NH, Saltz LB. Evolving treatment of advanced colon cancer. Annu Rev Med 2009; 60:207-19; PMID:19630571; http://dx.doi.org/10.1146/annurev.med.60. 041807.132435.
3. Blume-Jensen P, Hunter T. Oncogenic kinase signaling. Nature 2001; 411:335-6; http://dx.doi.org/10.1038/35077225.
4. Comes F, Matrone A, Lastella P, Nico B, Susca FC, Bagnulo R, et al. A novel cell type-specific role of p38α in the control of autophagy and cell death in colorectal cancer cells. Cell Death Differ 2007; 14:693-702; PMID:17159917; http://dx.doi.org/10.1038/sj.cdd.4402076.
5. Chiacchiera F, Grossi V, Cappellari M, Peserico A, Simonatto M, Germani A, et al. Blocking p38/ERK crosstalk affects colorectal cancer growth by inducing apoptosis in vitro and in preclinical mouse models. Cancer Lett 2012; 324:98-108; PMID:22579651; http://dx.doi.org/10.1016/j.canlet.2012.05.006.
6. Chiacchiera F, Matrone A, Ferrari E, Ingravallo G, Lo Sasso G, Murzilli S, et al. p38alpha blockade inhibits colorectal cancer growth in vivo by inducing a switch from HIF1alpha- to FoxO-dependent transcription. Cell Death Differ 2009; 16:1203-14; PMID:19343039; http://dx.doi.org/10.1038/cdd.2009.36.
7. Chiacchiera F, Simone C. Inhibition of p38alpha unveils an AMPK-FoxO3A axis linking autophagy to cancer-specific metabolism. Autophagy 2009; 5:1030-3; PMID:19587525; http://dx.doi.org/10.4161/auto.5.7.9252.
8. Chiacchiera F, Simone C. The AMPK-FoxO3A axis as a target for cancer treatment. Cell Cycle 2010; 9:1091-6; PMID:20190568; http://dx.doi.org/10.4161/ cc.9.6.11035.
9. Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol 2005; 6:322-7; PMID:15863380; http://dx.doi.org/10.1016/ S1470-2045(05)70168-6.
10. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999; 5:810-6; PMID:10395327; http://dx.doi.org/10.1038/10533.
11. Wickenden JA, Jin H, Johnson M, Gillings AS, Newson C, Austin M, et al. Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM. Oncogene 2008; 27:7150-61; PMID:18806830; http://dx.doi.org/10.1038/onc.2008.335.
12. Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004; 22:4456-62; PMID:15483017; http://dx.doi.org/10.1200/JCO.2004.01. 185.
13. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5:835-44; PMID:17016424; http://dx.doi.org/10. 1038/nrd2130.
14. Namboodiri HV, Bukhtiyarova M, Ramcharan J, Karpusas M, Lee Y, Springman EB. Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases. Biochemistry 2010; 49:3611-8; PMID:20337484; http://dx.doi.org/10.1021/bi100070r.
15. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-109; PMID:15466206; http://dx.doi.org/10.1158/0008-5472.CAN-04-1443.
16. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008; 7:3129-40; PMID:18852116; http://dx.doi.org/10.1158/1535-7163.MCT-08-0013.
17. Dal Lago L, D'Hondt V, Awada A. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist 2008; 13:845-58; PMID:18695262; http://dx.doi.org/10.1634/ theoncologist.2007-0233.
18. Matrone A, Grossi V, Chiacchiera F, Fina E, Cappellari M, Caringella AM, et al. p38alpha is required for ovarian cancer cell metabolism and survival. Int J Gynecol Cancer 2010; 20:203-11; PMID:20169663; http://dx.doi.org/10.1111/IGC. 0b013e3181c8ca12.
19. Gillissen B, Wendt J, Richter A, Richter A, Müer A, Overkamp T, et al. Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma. J Cell Biol 2010; 188:851-62; PMID:20308427; http://dx.doi.org/10.1083/jcb.200912070.
20. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 2008; 4:151-75; PMID:18188003.
21. Filomia F, De Rienzo F, Menziani MC. Insights into MAPK p38alpha DFG flip mechanism by accelerated molecular dynamics. Bioorg Med Chem 2010; 18:6805-12; PMID:20724167; http://dx.doi.org/10.1016/j.bmc.2010.07.047.
22. Kufareva I, Abagyan R. Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states. J Med Chem 2008; 51:7921-32; PMID:19053777; http://dx.doi.org/10.1021/jm8010299.
23. Carnero A. The PKB/AKT pathway in cancer. Curr Pharm Des 2010; 16:34-44; PMID:20214616; http://dx.doi.org/10.2174/138161210789941865.
24. Montagut C, Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 2009; 283:125-34; PMID:19217204; http://dx.doi.org/10.1016/ j.canlet.2009.01.022.
25. Dar AC, Das TK, Shokat KM, Cagan RL. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature 2012; 486:80-4; PMID:22678283; http://dx.doi.org/10.1038/nature11127.
26. Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 2010; 10:130-7; PMID:20094047; http://dx.doi.org/10.1038/nrc2787.
27. Pierotti MA, Tamborini E, Negri T, Pricl S, Pilotti S. Targeted therapy in GIST: in silico modeling for prediction of resistance. Nat Rev Clin Oncol 2011; 8:161-70; PMID:21364689; http://dx.doi.org/10.1038/nrclinonc.2011.3.
28. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006; 2:358-64; PMID:16783341; http://dx.doi.org/10.1038/nchembio799.